Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-DR7 is a specific probiotic strain of *Lactobacillus plantarum* developed by AB-BIOTICS. It is primarily targeted at improving respiratory health and supporting the immune system, specifically by reducing the duration and frequency of upper respiratory tract infections (URTIs). The strain works by modulating the gut-lung axis, enhancing the production of anti-inflammatory cytokines such as IL-10, and reducing pro-inflammatory markers like TNF-α and IFN-γ. Clinical studies have also suggested benefits in the gut-brain axis, including stress and anxiety reduction through the modulation of serotonin pathways and cortisol levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus plantarum DR7.